Skip to main content
Premium Trial:

Request an Annual Quote

Exosome Diagnostics, Intezyne to Develop Exosomal RNA Assay for Novel CRP Inhibitor

NEW YORK (GenomeWeb) – Exosome Diagnostics said today that it has agreed to collaborate with Intezyne to design and validate an exosomal RNA assay for use in Intezyne's Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor intended for the treatment of pancreatic, gastric, and other cancers in combination with existing anti-cancer therapies.

The assay will use Exosome Diagnostics' Exolution isolation kit and will be designed to stratify patients and monitor them longitudinally.

"As we delve further into the novel mechanism of action of IT-139, we needed a companion diagnostic assay that could reliably measure IT-139's impact on GRP78 levels," Suzanne Bakewell, VP of preclinical development at Intezyne, said in a statement.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.